HOME >> MEDICINE >> NEWS
Astrazeneca receives European approval for Seroquel; in bipolar mania

Sodertalje, Sweden, 13 October 2003 - AstraZeneca announced today that it has successfully completed the Mutual Recognition Procedure (MRP) involving 14 European countries to extend the use of SEROQUEL (quetiapine) to the treatment of mania associated with bipolar disorder (manic-depressive illness). SEROQUEL is also under review for bipolar mania in the United States with the FDA and in the UK with the MHRA.

"This approval is great news for clinicians involved in the treatment of bipolar disorder," commented Dr. Eduard Vieta, Director of Research, Department of Psychiatry, University of Barcelona. "The results from the clinical trial programme confirm that SEROQUEL holds real benefits for clinicians looking to treat the symptoms of the disease while keeping side effects to a minimum. This is of particular importance when treating patients with bipolar disorder since they can be particularly sensitive to treatment side effects which can in turn have a negative impact on compliance with medication."

Bipolar disorder is a serious mental illness that affects approximately 3-4% of the adult population and is the sixth leading cause of disability in the world.1,2,3,4 More than half of those with bipolar disorder stop taking their medication at some point during their illness, subjecting themselves to a high risk of relapse and an increased risk of suicide.5 This lack of compliance is strongly associated with the occurrence of side effects, therefore, a well tolerated and effective treatment is pivotal to the successful treatment of this condition.

Health authorities involved in the Mutual Recognition Procedure reviewed data from a comprehensive clinical trial programme in bipolar disorder undertaken by AstraZeneca, involving almost 1000 patients in 28 countries. The trials have delivered compelling results which confirm SEROQUEL to be an excellent first line therapy for the treatment of manic episodes associated with bipolar disorder.


'"/>

Contact: Rupert Doggett
rupert.doggett@shirehealthinternational.com
44-207-471-1500
Shire Health International
13-Oct-2003


Page: 1 2 3

Related medicine news :

1. UIC professor receives international humanitarian award
2. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
3. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
4. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
5. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
6. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
7. American Academy of Neurology program receives Grassroots Award
8. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
9. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
10. Pfizers antifungal medicine VFEND receives FDA approval
11. Shire receives US FDA approval of EQUETRO (TM) for bipolar disorder

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... ... September 19, 2017 , ... Presenting ... Benefit Administrators (SPBA) hosted “Expanding Your Success” with an educational emphasis. , ... focused on best practices for third party administrators (TPAs) related to health plan ...
(Date:9/19/2017)... ... September 19, 2017 , ... The Semper Fi Fund, one of ... release of a series of videos and a compelling documentary that provide unique insights ... United States as part of its ongoing mission. , Each of the videos focuses ...
(Date:9/19/2017)... ... September 19, 2017 , ... Public outrage over the toxins ... fallen on deaf ears, leaving the water industry itself to research, develop and ultimately ... of the curve in the field of natural alkaline water technologies, ...
(Date:9/19/2017)... (PRWEB) , ... September 19, ... ... memory-enhancing and cognitive health supplement developed by a neurosurgeon, has received a ... retailers. , Daily Brain Booster is currently available on the Wal-Mart ...
(Date:9/19/2017)... TX (PRWEB) , ... September 19, 2017 , ... ... the United States, named Dr. Howard Ng, as the new Medical Director of its ... be the new facility Medical Director of our Pflugerville- FM 685 location,” said Dr. ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
(Date:9/12/2017)... FRANCISCO , Sept. 12, 2017  ValGenesis ... Management Solutions (VLMS), is pleased to announce the ... a member of its Board of Directors and ... ValGenesis VLMS enables life science companies to manage ... the use of paper in this process. Furthermore, ...
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical Supplies, ... supplier of medical equipment, supplies, drugs, vaccines, and specialty ... entered into an agreement to acquire Vantage Medical Supplies, ... in Holtsville, New York . ... supplying new and emerging medical practices, will operate under ...
Breaking Medicine Technology:
Cached News: